Attorney Detail Banner
Back to Attorneys
Cork, Sarah

Sarah M. Cork, Ph.D.

Associate

sarahcork@quinnemanuel.com
Direct Tel: +1 213 443 3633, Direct Fax: +1 213 443 3100
Los Angeles
Tel: +1 213 443 3000 Fax: +1 213 443 3100

Dr. Sarah Cork is an associate in Quinn Emanuel’s Los Angeles office.  Sarah specializes in patent litigation in the life sciences sector, with an emphasis on pharmaceutical, BPCIA, Hatch-Waxman, medical device, patent inventorship, and drug product liability litigation.  Her experience spans a wide array of technologies including anti-cancer immunotherapies, modified insulins, ocular surgery methods, aortic stents, gene sequencing, oligo-based therapeutics, and small molecule drugs for HIV, dermatological, urological, ophthalmic, neurological, and cancer treatment.  She has also advised pharmaceutical companies in licensing and acquisition matters.   

Leveraging her extensive scientific training, Sarah understands her clients’ technology at a deep level, and she is skilled at translating complex technical concepts for a lay audience.  She has significant experience with all phases of litigation through trial and appeal, including motion practice, fact and expert discovery, witness preparation, and taking and defending depositions.  She has represented patentees and patent challengers in district courts and at the Federal Circuit.

Prior to her legal career, Sarah conducted research on neurological development and disorders.  Her graduate thesis work characterized novel biologic therapeutics for aggressive brain tumors. 

Sarah is a member of the Board of Directors of the Los Angeles IP Lawyers Association, and previously served as a co-administrator of the Giles S. Rich Inn of Court.

  • The University of Michigan
    (J.D., cum laude, 2014)
    • Michigan Telecommunications & Technology Law Review:
      • Editor in Chief
  • Emory University
    (PhD., Neuroscience, 2011)
  • Duke University
    (B.S., Biology; Biological Anthropology & Anatomy, With Distinction, 2005)
  • The State Bar of California
  • Super Lawyers “Rising Star” (2018 – 2019, 2021 – 2022)
  • S.M. Cork et al., A furin/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1, 31 ONCOGENE 5144–52 (2012)
  • S.M. Cork & E.G. Van Meir, Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature and tumor development, 89 J. MOL. MED. 743–52 (2011)
  • B. Kaur, S.M. Cork, et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism, 69 CANCER RES. 1212–20 (2009)